Key result
High-risk ML phenotypic clusters linked to ~2-fold higher post-alloHSCT cardiovascular events.
Why the study?
AlloHSCT recipients face substantial cardiovascular morbidity and mortality, and traditional risk stratification tools may not adequately capture the heterogeneity of cardiovascular risk in this population. Unsupervised ML phenotypic clustering was evaluated to identify distinct patient subgroups and their association with cardiovascular events.
Does machine learning-derived phenotypic clustering improve prediction of cardiovascular events in allogeneic hematopoietic stem cell transplant recipients?
Cohort (n=1,381)
No
Does machine learning-derived phenotypic clustering improve prediction of cardiovascular events in allogeneic hematopoietic stem cell transplant recipients?
Unsupervised machine learning-derived phenotypic clustering identifies distinct subgroups of allogeneic hematopoietic stem cell transplant recipients with significantly different risks of cardiovascular events, outperforming traditional transplant comorbidity indices.
Cluster 3/4 phenotypes associate with higher CV event rates; leaves open whether phenotyping aids risk stratification before prospective validation.
Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients face substantial cardiovascular morbidity and mortality. Traditional risk stratification tools may not adequately capture the heterogeneity of cardiovascular risk in this population. Phenotypic clustering using unsupervised machine learning (ML) approaches may identify distinct patient subgroups with differential cardiovascular risk profiles. Purpose To identify distinct phenotypic clusters among alloHSCT recipients and assess their association with cardiovascular events (CE). Methods We conducted a retrospective cohort study of 1,381 consecutive patients who underwent alloHSCT at Saint-Louis Hospital (Paris, France) between July 2011 and July 2023. We applied a Latent Class Model, a probabilistic unsupervised ML approach, to baseline demographic, clinical, biological, echocardiographic, and transplant-related variables. Final clustering was selected based on statistical robustness and clinical relevance. A decision tree classifier was developed to predict cluster membership. The primary outcome was a composite of CE including cardiovascular death, heart failure, atrial fibrillation/flutter, ventricular tachycardia, and conductive disorders resulting in pacemaker implantation, and acute arterial events (acute coronary syndrome, ischaemic stroke). Cox proportional hazards models were used to assess the prognostic significance of each phenotypic cluster to predict the primary outcome. Results Four distinct phenotypic clusters were identified: Cluster 1 (28%) comprised young patients with non-malignant hematologic diseases; Cluster 2 (38%) included young patients with malignancies and high cardiotoxic therapy exposure; Cluster 3 (35%) consisted of older patients with myeloproliferative/myelodysplastic syndromes; and Cluster 4 (6%) represented patients with the highest cardiovascular risk burden. During a median follow-up of 3 (1-6) years, 247 patients (18%) experienced CE. Kaplan-Meier survival curves demonstrated significant differences in CE-free survival across clusters (log-rank test p<0.001) (Figure 1). Compared to Cluster 1, Cluster 3 (adjusted HR: 1.80, 95% CI: 1.07-3.03, p=0.026) and Cluster 4 (adjusted HR: 2.00, 95% CI: 1.08-3.71, p=0.027) were independently associated with higher risk of CE. A decision tree classifier achieved 87% accuracy using five readily available variables (Figure 2). Phenotypic clustering significantly improved cardiovascular risk prediction beyond the hematopoietic stem cell transplantation-comorbidity index (C-statistic improvement: 0.08, integrative discrimination index: 0.050, net reclassification index: 0.640, all p<0.001). Conclusion ML-derived phenotypic clustering identifies distinct patient subgroups with differential cardiovascular risk among alloHSCT recipients. This approach may enhance risk stratification and guide personalized cardiovascular surveillance and prevention strategies.
No takes yet. Share an insight, caveat, or question.
Gonçalves et al. (2026) conducted a cohort in Allogeneic hematopoietic stem cell transplantation recipients (n=1,381). ML-derived phenotypic clusters (Cluster 4: highest cardiovascular risk burden; Cluster 3: older patients with myeloproliferative/myelodysplastic syndromes) vs. Cluster 1 (young patients with non-malignant hematologic diseases) was evaluated on Composite of cardiovascular events including cardiovascular death, heart failure, atrial fibrillation/flutter, ventricular tachycardia, conductive disorders resulting in pacemaker implantation, and acute arterial events (acute coronary syndrome, ischaemic stroke) (HR 2.00, 95% CI 1.08-3.71, p=0.027). High-risk ML phenotypic clusters (Cluster 3: HR 1.80, 95% CI 1.07-3.03; Cluster 4: HR 2.00, 95% CI 1.08-3.71) independently predicted cardiovascular events after alloHSCT vs Cluster 1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: